Home Tags SH Abivax SA

SH Abivax SA Related Content

inflammatory bowel diseases

Changing the treatment paradigm in Inflammatory Bowel Diseases

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.

Follow Open Access Government